OSSURE® Local Osteo-Enhancement Procedure (LOEP®) is a minimally invasive surgical procedure. It involves the injection of a calcium-based biomaterial (AGN1) into an area of osteoporotic bone loss, where –according to the manufacturer- it reportedly provides immediate strength. The intended outcome is increased bone strength and preventing fragility fractures. AGN1 LOEP is a once-off minimally invasive surgical treatment that aims to resorb and replace the implant material with new bone. AGN1 LOEP is approved in Europe with the CE mark (in 2017) and in the USA, the Food and Drug Administration (FDA) has granted OSSURE LOEP 2020 a Breakthrough Device Designation for the treatment of stable vertebral compression fractures.